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October 2015nonmajor clinically relevant bleeding (HRs 0.98 and 1.09; interaction P = .17), and intracerebral hemorrhage (HRs 0.62 and
0.72; interaction P = .67) was independent of DM status. Adjusted exploratory analyses suggested 1.3-, 1.5-, and 1.9-fold
higher 2-year rates of stroke, vascular mortality, and myocardial infarction in DM patients.
Conclusions and Relevance The relative efficacy and safety of rivaroxaban vs warfarin was similar in patients
with and without DM, supporting use of rivaroxaban as an alternative to warfarin in diabetic patients with AF. (Am Heart J
2015;170:675-682.e8.)Theprevalence of both atrial fibrillation (AF) and diabetes
mellitus (DM) are rising. The 2 conditions commonly occur
together, and DM is an independent risk factor for stroke in
patientswith AF (relative risk 1.7).1 Diabetic patientswith a
stroke have higher mortality rates than nondiabetic
patients.2 Intensive activation of the coagulation system,
decreased fibrinolytic activity, and alterations in platelet and
endothelial function, accompanied by increased levels of
tissue plasminogen activator antigen and factor VIII activity,
may serve as links between diabetes and AF-related stroke.3
Diabetic patients demonstrate a larger left atrial diameter
and left atrial appendage size with higher prevalence of left
atrial or appendage thrombi than do nondiabetic patients.4
Traditionally, diabetic patients with AF have been treated
with vitaminK antagonistswith good efficacy. Rivaroxaban,
the first oral factor Xa inhibitor approved as an alternative to
warfarin, was noninferior to adjusted-dose warfarin (target
international normalized ratio [INR] 2.0-3.0) in ROCKET
AF5,6 among patients with nonvalvular AF at moderate-to-
high risk of stroke and caused less intracranial and fatal
bleeding. The efficacy and safety of rivaroxaban in patients
with AF and DM has not been specifically described. We
compared rates of stroke and systemic embolism (primary
events) as well as safety end points (bleeding on treatment)
in those randomized to rivaroxaban or warfarin to ascertain
the influence of DM on these outcomes.
Materials and methods
The design and results of the ROCKET AF trial
(ClinicalTrials.gov NCT00403767) have been described.
Briefly, thiswas an international,multicenter, double-blind,
double-dummy, randomized noninferiority trial that com-
pared rivaroxaban—20 mg once daily (or 15 mg daily in
patients with creatinine clearance 30-49 mL/min)—with
adjusted-dose warfarin (target INR 2.5, range 2.0-3.0) in
patients with nonvalvular AF. Patients with electrocardio-
graphic documentation of AF, at moderate-to-high risk of
stroke, were eligible for enrollment. Stroke risk was
defined by CHADS2 risk score ≥2: (clinical heart failure,
hypertension, age≥75 years, DM [1 point each], and prior
stroke or transient ischemic attack [TIA; 2 points]).
Enrollment of patients with only 2 risk factors was capped
at 10% for each clinical site. Key exclusion criteria included
prosthetic heart valves, hemodynamically significant mitral
stenosis, creatinine clearance b30 mL/min, recent embolic
event, and an elevated risk of bleeding. The institutionalreview boards at each participating site approved the
protocol, and all patients provided written consent. The
ROCKET AF trial was sponsored by Johnson & Johnson
Pharmaceutical Research &Development (Raritan, NJ) and
Bayer HealthCare AG (Leverkusen, Germany).
Definition of diabetes
The diagnosis of DM was based on either prior
documentation of DM or treatment with glucose-lowering
medications. Measures of glycemic control, including
glycated hemoglobin and blood glucose, were not
systematically recorded.
Outcomes definitions
The primary efficacy outcome for the ROCKET AF trial
and this prespecified analysis was stroke (ischemic or
hemorrhagic) or non–central nervous system embolism.
Detection of primary end points was enhanced by a
standardized stroke symptom questionnaire, computed
tomography or magnetic resonance brain imaging, and
additional evaluation by local study-affiliated neurologists
or stroke specialists blinded to treatment. The secondary
efficacy outcomes included all-cause death, myocardial
infarction (MI), and the composite (and individual
components) of stroke, systemic embolism, or vascular
death. The intention-to-treat population was used for all
efficacy analyses. Ninety-three patients from one site
were excluded because of violations of Good Clinical
Practice guidelines. Efficacy end points were measured
until the time of site notification of study termination.
The primary safety end point was major or nonmajor
clinically relevant (NMCR) bleeding. Secondary safety
end points were intracranial hemorrhage (ICH) and
hemorrhagic stroke. Safety analyses were based on the
safety population of randomized patients who received
≥1 dose of study drug. A per-protocol sensitivity analysis
used the subset of patients from the safety population
without protocol violations. For safety and per-protocol
analyses, end points were measured from the first dose
until 2 days after the last dose of study medication. All
events were adjudicated by an independent clinical
events committee blinded to treatment assignment.
Statistical analysis
Categorical data are summarized as counts and percent-
ages, and differences were tested with the Pearson χ2 test;
continuous variables are summarized as medians with
Table I. Baseline characteristics by treatment assignment
Diabetic patients (n = 5695) Nondiabetic patients (n = 8569)
Rivaroxaban
(n = 2878)
Warfarin
(n = 2817)
Rivaroxaban
(n = 4253)
Warfarin
(n = 4316)
Baseline characteristics
Age (y), median (25th, 75th) 71 (64, 77) 71 (64, 77) 74 (66, 79) 74 (66, 79)
Female, no. (%) 1128 (39.2) 1114 (39.5) 1702 (40.0) 1716 (39.8)
AF, no. (%)
Persistent 2358 (81.9) 2326 (82.6) 3428 (80.6) 3436 (79.6)
Paroxysmal 475 (16.5) 447 (15.9) 770 (18.1) 822 (19.0)
Newly diagnosed 45 (1.6) 44 (1.6) 55 (1.3) 58 (1.3)
Type of diabetes control, no. (%)
Diet 747 (26.0) 707 (25.1)
Oral medication 1675 (58.2) 1626 (57.7)
Thiazolidinedione 88 (5.3) 101 (6.2)
Biguanide 931 (55.6) 933 (57.4)
Sulfonylurea 902 (53.9) 913 (56.2)
Other/unspecified 57 (3.4) 60 (3.7)
Insulin 456 (15.8) 483 (17.2)
Presenting characteristics
BMI (kg/m2), median (25th, 75th) 30.0 (26.6, 34.2) 29.8 (26.4, 34.2) 27.3 (24.4, 30.7) 27.2 (24.4, 30.4)
Systolic BP (mm Hg), median (25th, 75th) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140)
Diastolic BP (mm Hg), median (25th, 75th) 80 (70, 85) 80 (70, 85) 80 (70, 85) 80 (72, 86)
CrCl (mL/min), median (25th, 75th) 73 (56, 94) 72 (54, 93) 65 (50, 83) 65 (51, 82)
eGFR (mL/min), no. (%)
b30 6 (0.2) 5 (0.2) 6 (0.1) 11 (0.3)
30-60 920 (32.0) 956 (34.0) 1813 (42.7) 1808 (41.9)
N60 1950 (67.8) 1853 (65.8) 2428 (57.2) 2494 (57.8)
Other baseline comorbidities
Prior stroke/TIA, no. (%) 922 (32.0) 884 (31.4) 2832 (66.6) 2830 (65.6)
Hypertension, no. (%) 2738 (95.1) 2695 (95.7) 3698 (87.0) 3779 (87.6)
Congestive HF, no. (%) 1893 (65.8) 1899 (67.4) 2574 (60.5) 2542 (58.9)
COPD, no. (%) 325 (11.3) 337 (12.0) 429 (10.1) 406 (9.4)
CHADS2 score, median (25th, 75th) 3 (3, 4) 3 (3, 4) 3 (3, 4) 3 (3, 4)
CHADS2 score, mean (SD) 3.7 (1.0) 3.7 (1.0) 3.3 (0.9) 3.3 (0.9)
Medications, no. (%)
Prior VKA 1870 (65.0) 1847 (65.6) 2573 (60.5) 2614 (60.6)
Prior chronic ASA 1114 (38.7) 1116 (39.6) 1612 (37.9) 1643 (38.1)
ACE inhibitor/ARB 2345 (81.5) 2281 (81.0) 2973 (69.9) 2984 (69.1)
β-Blocker 1912 (66.4) 1922 (68.2) 2683 (63.1) 2733 (63.3)
Calcium-channel blocker 917 (31.9) 890 (31.6) 1100 (25.9) 1051 (24.4)
Diuretic 1921 (66.7) 1899 (67.4) 2345 (55.1) 2325 (53.9)
Abbreviations: BMI, Body mass index; BP, blood pressure; CrCl, creatinine clearance; HF, heart failure; VKA, vitamin K antagonist; ASA, aspirin; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker.
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Wilcoxon rank sum test. Outcomes are presented as events
per 100 patient-years. Cox proportional hazards models
were used to assess the associations with risk of outcomes
for patients with vs without DM and for rivaroxaban vs
warfarin within diabetic and nondiabetic subgroups. Models
for the latter included a term for the interaction between
randomized treatment and the subgroup of interest.
All models included covariates identified as predictive
of outcomes by modeling in the full ROCKET AF cohort.
For efficacy end points, these included age, sex, body
mass index, geographical region, previous stroke or TIA,
previous MI, peripheral arterial disease, carotid occlusive
disease, hypertension, chronic obstructive pulmonarydisease (COPD), paroxysmal AF, left ventricular ejection
fraction, heart rate, diastolic blood pressure, estimated
glomerular filtration rate (eGFR) at baseline (calculated
using the Cockroft-Gault formula), and abstinence from
alcohol use. In the safety analysis, the following variables
were entered into the model: age, sex, region, previous
stroke or TIA, gastrointestinal bleeding, COPD, diastolic
blood pressure, eGFR, anemia, platelet count, albumin,
prior aspirin use, and prior use of a vitamin K antagonist
or thienopyridine. An additional per-protocol sensitivity
analysis examined the primary efficacy end point, major
or NMCR bleeding, and hemorrhagic stroke in the
per-protocol population, with models performed in the
same manner. Risk relationships are presented as
Table II. Observed and predicted 2-year event rates (95% CIs)
Diabetic Nondiabetic
2-y Kaplan-Meier rate
Predicted 2-y rate
with covariate
values from the
nondiabetic group 2-y Kaplan-Meier rate
Predicted 2-y rate with
actual covariate values
Efficacy outcomes
Stroke or SE 3.85 (3.31-4.40) 5.26 (5.21-5.31) 4.40 (3.93-4.86) 4.44 (4.40-4.48)
Ischemic stroke or SE 2.99 (2.51-3.47) 4.01 (3.97-4.05) 3.52 (3.10-3.94) 3.53 (3.50-3.57)
Stroke/SE/vascular death 8.97 (8.16-9.78) 11.52 (11.42-11.63) 8.30 (7.66-8.94) 8.33 (8.25-8.41)
Stroke/SE/vascular death/MI 10.73 (9.85-11.60) 13.26 (13.13-13.38) 9.41 (8.73-10.08) 9.39 (9.31-9.48)
Stroke 3.62 (3.09-4.14) 5.32 (5.27-5.36) 4.08 (3.63-4.53) 4.10 (4.07-4.14)
Ischemic stroke 2.75 (2.29-3.21) 4.07 (4.03-4.10) 3.20 (2.80-3.60) 3.20 (3.17-3.23)
SE 0.28 (0.12-0.43) 0.17 (0.17-0.17) 0.37 (0.23-0.51) 0.39 (0.38-0.40)
Vascular death 6.23 (5.55-6.92) 7.91 (7.80-8.02) 5.12 (4.61-5.63) 5.15 (5.08-5.22)
MI 2.60 (2.16-3.04) 2.92 (2.87-2.96) 1.57 (1.28-1.85) 1.51 (1.49-1.54)
Safety outcomes
Major or NMCR bleeding 24.74 (23.41-26.08) 25.67 (25.47-25.87) 24.08 (23.01-25.15) 24.16 (23.97-24.35)
Major bleeding 7.22 (6.41-8.04) 7.52 (7.42-7.63) 6.11 (5.51-6.71) 6.35 (6.27-6.44)
Intracranial hemorrhage 1.30 (0.93-1.66) 1.72 (1.69-1.75) 1.10 (0.84-1.36) 1.18 (1.16-1.20)
Hemorrhagic stroke 0.68 (0.42-0.95) 0.91 (0.89-0.94) 0.65 (0.46-0.84) 0.71 (0.69-0.73)
Abbreviation: SE, Systemic embolism.
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the adjusted Cox models.
To address covariate imbalance, we calculated mean
predicted event rates at 1 and 2 years to compare rates for
nondiabetic patients vs rates expected in diabetic
patients with the same prevalence of comorbid condi-
tions as the nondiabetic group. We also performed a
propensity score–matched analysis for the primary
efficacy and safety outcomes to test the robustness of
the multivariable adjusted models (see Supplementary
Information for detailed methods).
The time anticoagulation was in the therapeutic range
among patients treated with warfarin calculated using
the linear interpolation method of Rosendaal et al.7
Statistical significance was accepted at the 95% confi-
dence level (P b .05). All analyses were performed with
the SAS version 9.2 statistical software (SAS Institute,
Cary, NC).
Results
The ROCKET AF trial included 14,264 patients, of whom
5,695 (39.9%) hadDM,with amedian follow-up of 1.9 years.
Because DM was one of the entry criteria associated with
risk of stroke in patientswith AF, participantswithDMwere
younger, on average, and less than half as often had prior
stroke or TIA, but more often had a CHADS2 score of 5 or
6 (Table I and online Appendix Supplementary Table I). In
addition, diabetic participants had a higher body mass
index and higher frequency of hypertension, heart failure,
COPD, and use of angiotensin inhibitor, β-adrenergic
antagonist, calcium-channel blocker, and diuretic medica-tions at baseline. Glucose-lowering therapy was not used
for 25.5% of diabetic study participants; 16.5%were treated
with insulin, with or without concomitant oral agents, and
58% received oral agents alone (5.7% thiazolidinediones,
65.5% biguanides, and 55% sulfonylureas). Guided by renal
function, the dose of rivaroxaban assigned to patients with
DM was 20 mg once daily in 84% and reduced to 15 once
daily in 16%, compared with 76% and 24% in patients
without DM.Outcomes in patients with and without diabetes
Vascular death rates were 3.24 vs 2.63 (P = .0001) andMI
rates were 1.35 vs 0.75 (P b .0001) per 100 patient-years in
diabetic vs nondiabetic patients, respectively (online
Appendix Supplementary Table II). In evaluating the
unadjusted risk for stroke associated with each of the
CHADS2 risk factors, DM was not a significant predictor
(online Appendix Supplementary Table III). Observed rates
of stroke, systemic embolism, and bleeding among diabetic
patients were either similar to or lower than among
nondiabetic patients (online Appendix Supplementary
Table II). We used Cox regression modeling to predict
outcomes for diabetic patients with the same prevalence
of comorbid conditions as nondiabetic patients at 2 years.
By this extrapolation, patients with DM faced a 1.3-fold
higher risk of stroke, 1.5-fold higher risk of vascular
death, and 1.9-fold higher risk of MI. Rates of major
bleeding, hemorrhagic stroke, and ICHwere 1.2, 1.3, and
1.5 times greater than those in nondiabetic patients,
respectively (Table II).
Figure
Primary events in patients with and without diabetes randomized to warfarin vs rivaroxaban. The efficacy of rivaroxaban compared with warfarin
in diabetic participants was similar to that in nondiabetic patients. Diabetic patients appear to have a lower rate of events than do nondiabetic
patients due to covariate imbalance. Please see Table II for covariate adjusted rates.
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In patients with DM randomized to rivaroxaban vs
warfarin, rates of primary events (1.74 vs 2.14 per 100
patient-years) were similar to those in patients without DM
(2.12 vs 2.32 per 100 patient-years; interaction P = .53)
(Figure and Table III). The same was true for rates of
ischemic stroke and systemic embolism (1.48 vs 1.55 per
100 patient-years in patients with DM, and 1.71 vs 1.80 per
100 patient-years in thosewithout DM; interaction P = .91).
Additional efficacy outcomes were independent of DM
status (online Appendix Supplementary Figure 1). Results
were similar across multiple subgroups (online Appendix
Supplementary Table IVA-D).
Rates of major bleeding in patients with DM randomized
to rivaroxaban vs warfarin (3.79 vs 3.90 per 100 patient-
years)were similar to those in patientswithout DM (3.47 vs
3.17 per 100 patient-years; interaction P = .43). The same
was true for rates of NMCR bleeding (14.81 vs 15.44 per
100 patient-years in patients with DM, and 14.99 vs 13.94
per 100 patient-years in those without DM; interaction
P = .17) and ICH (0.50 vs 0.82 per 100 patient-years in
patients with DM, and 0.49 vs 0.69 per 100 patient-years
in those without DM; interaction P = .67) (Table III and
online Appendix Supplementary Figure 2). Additionalsafety outcomes were similar regardless of DM status
(online Appendix Supplementary Figure 2), and results
were also similar across multiple subgroups (online
Appendix Supplementary Table IVC and D).
When examined in propensity score–matched cohorts,
the results were unchanged (online Appendix Supplemen-
tary Tables V and VIA-D). Similarly, the efficacy and safety
impact of rivaroxaban compared with warfarin was not
affected by diet or use of oral hypoglycemic agents or insulin
therapy for glycemic control (online Appendix Supplemen-
tary Table IVA-D; interaction P, not significant).Discussion
ROCKET AF enrolled a greater proportion of patients with
DM (5,695 [39.9%]) than did other completed contemporary
trials of novel oral anticoagulants (4,221 [23.3%] in the
Randomized Evaluation of Long-term Anticoagulant Therapy
[RE-LY] trial with dabigatran; 1,096 [19.2%] in the Apixaban
Versus Acetylsalicylic Acid to Prevent Strokes [AVERROES]
trial; 4,547 [25%] in theApixaban forReductionof Stroke and
Other Thromboembolic Events in Atrial Fibrillation [ARIS-
TOTLE] trial; and 7,624 [36%] in Effective Anticoagulation
with Factor Xa Next Generation in Atrial Fibrillation–
Table III. Treatment comparisons for efficacy and safety end points in diabetic and nondiabetic patients
Diabetic patients Nondiabetic patients
P value for
interaction⁎
Rivaroxaban
events/100 pt-yrs
(total events)
Warfarin
events/100 pt-yrs
(total events)
Rivaroxaban
vs warfarin
HR (95% CI)
Rivaroxaban
events/100 pt-yrs
(total events)
Warfarin
events/100 pt-yrs
(total events)
Rivaroxaban
vs warfarin
HR (95% CI)
Efficacy outcomes
Stroke or SE 1.74 (95) 2.14 (114) 0.82 (0.63-1.08) 2.12 (174) 2.32 (192) 0.92 (0.75-1.13) .53
Ischemic stroke or SE 1.48 (81) 1.55 (83) 0.97 (0.72-1.32) 1.71 (141) 1.80 (150) 0.95 (0.76-1.20) .91
Stroke/SE/vascular death 4.23 (224) 5.17 (267) 0.84 (0.70-1.00) 4.34 (348) 4.22 (342) 1.03 (0.89-1.19) .081
Stroke/SE/vascular death/MI 5.15 (270) 6.26 (320) 0.84 (0.72-0.99) 4.88 (389) 4.83 (389) 1.01 (0.88-1.17) .097
Stroke 1.61 (88) 2.05 (109) 0.80 (0.60-1.06) 2.01 (165) 2.07 (172) 0.97 (0.79-1.21) .27
Ischemic stroke 1.35 (74) 1.45 (78) 0.94 (0.69-1.30) 1.60 (132) 1.56 (130) 1.03 (0.81-1.31) .67
SE 0.14 (8) 0.11 (6) 1.37 (0.48-3.96) 0.14 (12) 0.25 (21) 0.58 (0.29-1.19) .19
Vascular death 2.83 (152) 3.65 (192) 0.80 (0.64-0.99) 2.73 (223) 2.53 (209) 1.08 (0.89-1.30) .037
MI 1.19 (65) 1.51 (81) 0.82 (0.59-1.14) 0.78 (65) 0.72 (61) 1.09 (0.77-1.54) .25
Safety outcomes
Major or NMCR bleeding 14.81 (582) 15.44 (596) 0.98 (0.88-1.10) 14.99 (893) 13.94 (853) 1.09 (0.99-1.20) .17
Major bleeding 3.79 (165) 3.90 (169) 1.00 (0.81-1.24) 3.47 (230) 3.17 (217) 1.12 (0.93-1.35) .43
Intracranial hemorrhage 0.50 (22) 0.82 (36) 0.62 (0.36-1.05) 0.49 (33) 0.69 (48) 0.72 (0.46-1.12) .67
Hemorrhagic stroke 0.23 (10) 0.46 (20) 0.51 (0.24-1.09) 0.28 (19) 0.43 (30) 0.65 (0.37-1.16) .61
Intraocular/retinal bleeding 0.14 (6) 0.25 (11) 0.53 (0.20-1.45) 0.16 (11) 0.19 (13) 0.89 (0.40-1.99) .43
Abbreviations; pt-yrs, Patient-years; SE, systemic embolism.
⁎ P value for interaction of diabetes and treatment.
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48] trial with edoxaban), allowing robust assessment of an
alternative towarfarin in diabetic patientswith nonvalvular
AF. The adjusted rates of stroke and systemic embolism and
bleeding were higher for patients with DM vs without DM.
The efficacy and safety of rivaroxaban compared with
warfarin evident in the overall ROCKET AF study extended
to patients with DM, and these effects were not
significantly impacted by the use of oral agents or insulin
for glucose control. Our results are consistentwith findings
from a subanalysis of the RELY trial in diabetic patients,
which showed that diabetic status does not appear to impact
the relative safety and efficacy of dabigatran compared
with warfarin.8
In the Atherosclerosis Risk in Communities (ARIC)
study of 13,025 persons, DM was associated with a 35%
increase in the incidence of AF, and risk was greater in
those with elevated levels of glycated hemoglobin.9
These observations are supported by a population-based
study and meta-analysis of more than 100,000 cases of AF
among more than 1.6 million persons.10,11 In the United
Kingdom Prospective Diabetes Study (UKPDS), diabetic
patients with AF had an 8-fold greater risk of stroke than
did patients without this risk factor.12 In cohorts of
patients with AF, those with DM had stroke rates ranging
from 3.6% to 8.6% per year.13,14 In the Stroke Prevention
in Atrial Fibrillation (SPAF) studies, of 196 diabetic
patients without hypertension, prior stroke, or TIA,
other than in women older than 75 years, the ischemic
stroke rate was 2.6% per year.15 The mechanism bywhich DM raises stroke risk independent of other
established risk factors is unknown, but a hypercoagula-
ble milieu mediated through increased levels of tissue
plasminogen activator antigen and factor VIII activity and
decreased fibrin breakdown is one postulated factor.16
Inferences about differences in clinical characteristics
or intrinsic risk of stroke in the diabetic subpopulations in
recent trials must be tempered because DM is a
component of the CHADS2 stroke risk schema used to
define eligibility for enrollment. Although we found
similar rates of stroke and systemic embolism in patients
with and without DM, the latter group was more likely to
have had prior stroke. As would be expected, patients
with DM had a higher likelihood of MI and vascular death
than did nondiabetic participants. The lack of robust
association between DM and stroke in this analysis may
be driven by high thromboembolism risk in the ROCKET
AF population (mean CHADS2 score 3.5). Given the
considerably less frequent history of stroke, the diabetic
subpopulation of the ROCKET AF cohort might be
expected to have a lower event rate than the nondiabetic
group; yet, the rates were comparable, suggesting that
DM is associated with considerable risk. Modeling 2-year
event rates for diabetic patients using the comorbid
profiles of nondiabetic patients unmasked a higher risk of
events associated with DM. The results of this analysis
suggest that DM influences stroke risk in patients with AF
as much as it raises the risk of coronary events in patients
with atherosclerosis, but whether these associations
share common mechanisms is speculative.
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The results reported here are derived from prespecified,
post hoc subgroup analyses of a randomized trial in which
DM was among the criteria used to establish eligibility for
entry. Although the time in therapeutic range in ROCKETAF
was lower than reported in some studies, the efficacy of
rivaroxaban was favorable across groups defined by INR
control in the overall trial population. The especially high
mean CHADS2 risk score required for enrollment provides a
robust test of the drug's efficacy and safety in high-risk
patients, butmay limit generalizability to patientswithDMat
lower thromboembolism risk. Finally, we have inadequate
information regarding the influence of glycemic control on
clinical outcomes to assess whether more aggressive
management of blood glucose influences the risk of
ischemic or hemorrhagic events in patientswithDMandAF.Conclusions
The relative efficacy and safety of rivaroxaban com-
pared with warfarin was similar in patients with and
without DM, supporting the use of rivaroxaban as an
alternative to warfarin for prevention of stroke and
systemic embolism in diabetic patients with AF.
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Volume 170, Number 4Appendix. Supplementary informationSupplementary Table I. Baseline characteristics by diabetes status
All patients enrolled
(N = 14,264)
Diabetic patients
(n = 5695)
Nondiabetic patients
(n = 8569) P
Baseline characteristics
Age (y), median (25th, 75th) 73 (65, 78) 71 (64, 77) 74 (66, 79) b.0001
Female, no. (%) 5660 (39.7) 2242 (39.4) 3418 (39.9) .53
AF, no. (%) .0007
Persistent 11,548 (81.0) 4684 (82.2) 6864 (80.1)
Paroxysmal 2514 (17.6) 922 (16.2) 1592 (18.6)
Newly diagnosed 202 (1.4) 89 (1.6) 113 (1.3)
Diabetes controlled⁎ by, no. (%)
Diet 1454 (25.5)
Oral medication† 3301 (58.0)
Thiazolidinedione 189 (5.7)
Biguanide 1864 (56.5)
Sulfonylurea 1815 (55.0)
Other/unspecified 117 (3.5)
Insulin 939 (16.5)
Presenting characteristics, median (25th, 75th)
Body mass index (kg/m2) 28.2 (25.1, 32.0) 29.9 (26.5, 34.2) 27.2 (24.4, 30.5) b.0001
Systolic blood pressure 130 (120, 140) 130 (120, 140) 130 (120, 140) b.0001
Diastolic blood pressure 80 (70, 85) 80 (70, 85) 80 (71, 86) b.0001
Creatinine clearance 67 (52, 87) 72 (55, 94) 65 (50, 83) b.0001
eGFR (mL/min) b.0001
b30 28 (0.2) 11 (0.2) 17 (0.2)
30-60 5497 (38.6) 1876 (33.0) 3621 (42.3)
N60 8725 (61.2) 3803 (66.8) 4922 (57.5)
Other baseline comorbidities
Prior stroke/TIA, no. (%) 7468 (52.4) 1806 (31.7) 5662 (66.1) b.0001
Hypertension, no. (%) 12,910 (90.5) 5433 (95.4) 7477 (87.3)
Congestive heart failure, no. (%) 8908 (62.5) 3792 (66.6) 5116 (59.7) b.0001
COPD, no. (%) 1497 (10.5) 662 (11.6) 835 (9.8) .0003
CHADS2 score, median (25th, 75th) 3 (3, 4) 3 (3, 4) 3 (3, 4) b.0001
CHADS2 score, mean (SD) 3.5 (0.9) 3.7 (1.0) 3.3 (0.9)
Medications, no. (%)
Prior vitamin K antagonist use 8904 (62.4) 3717 (65.3) 5187 (60.5) b.0001
Prior chronic ASA use 5485 (38.5) 2230 (39.2) 3255 (38.0) .16
ACE inhibitor/ARB 10,583 (74.2) 4626 (81.2) 5957 (69.5) b.0001
β-Blocker 9250 (64.8) 3834 (67.3) 5416 (63.2) b.0001
Calcium-channel blocker 3958 (27.7) 1807 (31.7) 2151 (25.1) b.0001
Diuretic 8490 (59.5) 3820 (67.1) 4670 (54.5) b.0001
Abbreviations: eGFR, Estimated glomerular filtration rate; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; ASA, aspirin; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker.
⁎ Patients may have reported more than one type of diabetes control. In this table, patients are placed in mutually exclusive categories with the priority order of (1) insulin, (2) oral,
and (3) no treatment.
† Percents for individual drug types are calculated among those with diabetes controlled by oral medication. Patients could report more than 1 medication. In total, 438 (13%) of
those reporting control by oral medication did not have any diabetes-specific medication reported.
Supplementary Table II. Efficacy and safety end points in diabetic and nondiabetic patients
Diabetic patients
events/100 pt-yrs
(total events)
Nondiabetic patients
events/100 pt-yrs
(total events)
Diabetic patients vs
nondiabetic patients
HR (95% CI) P
Efficacy outcomes
Stroke or SE 1.94 (209) 2.22 (366) 1.13 (0.94-1.35) .20
Ischemic stroke or SE 1.52 (164) 1.76 (291) 1.15 (0.94-1.41) .18
Stroke/SE/vascular death 4.69 (491) 4.28 (690) 1.27 (1.13-1.44) .0001
Stroke/SE/vascular death/MI 5.70 (590) 4.86 (778) 1.32 (1.18-1.49) b.0001
Stroke 1.83 (197) 2.04 (337) 1.18 (0.98-1.43) .085
Ischemic stroke 1.40 (152) 1.58 (262) 1.23 (0.99-1.52) .063
SE 0.13 (14) 0.20 (33) 0.67 (0.34-1.33) .25
Vascular death 3.24 (344) 2.63 (432) 1.35 (1.16-1.57) .0001
MI 1.35 (146) 0.75 (126) 1.70 (1.31-2.20) b.0001
Safety outcomes
Major or NMCR bleeding 15.12 (1178) 14.46 (1746) 1.02 (0.94-1.10) .62
Major bleeding 3.85 (334) 3.32 (447) 1.13 (0.97-1.31) .12
Intracranial hemorrhage 0.66 (58) 0.59 (81) 1.36 (0.94-1.96) .10
Hemorrhagic stroke 0.34 (30) 0.36 (49) 1.14 (0.69-1.88) .62
Intraocular/retinal bleed 0.19 (17) 0.18 (24) 1.04 (0.52-2.06) .91
Event rates (events per 100 pt-yrs) are unadjusted. HRs and P values are from adjusted Cox models.
Abbreviations: pt-yrs, Patient-years; HR, hazard ratio; MI, myocardial infarction; SE, systemic embolism; NMCR, nonmajor clinically relevant.
Supplementary Table III. Risk associated with diabetes compared with other components of the CHADS2 score
Variable
Stroke/SE Ischemic stroke/SE
HR (95% CI) P HR (95% CI) P
Diabetes 1.14 (0.95-1.37) .16 1.16 (0.94-1.42) .17
Other CHADS2 risk factors
Age N75 y 1.22 (1.01-1.47) .034 1.22 (0.99-1.50) .063
Hypertension 1.26 (0.93-1.71) .14 1.09 (0.79-1.51) .61
LV dysfunction or heart failure 0.93 (0.78-1.11) .41 0.96 (0.79-1.17) .71
Chronic kidney disease (CrCl 30-49 mL/min) 1.26 (1.02-1.56) .030 1.39 (1.10-1.75) .0059
Female sex 1.29 (1.08-1.55) .0044 1.36 (1.12-1.66) .0024
Warfarin treatment assignment 1.13 (0.96-1.34) .13 1.05 (0.87-1.26) .64
Each model adjusted for other known predictors of efficacy end points.
Abbreviations: HR, Hazard ratio; SE, systemic embolism; LV, left ventricle; CrCl, creatinine clearance.
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Supplementary Table IV. End points by treatment in diabetic subgroups
N
Rivaroxaban
events/100 pt-yrs
(total events)
Warfarin
events/100 pt-yrs
(total events)
Rivaroxaban vs
warfarin HR
(95% CI)
P value for interaction
of subgroup⁎ with
treatment
A. Stroke or systemic embolism
Diabetic subgroup
Diabetes controlled by
Insulin 930 1.88 (16) 1.73 (16) 1.18 (0.59-2.36) .62
Oral medication 3283 1.80 (58) 2.27 (70) 0.78 (0.55-1.10)
Diet 1433 1.53 (21) 2.13 (28) 0.72 (0.41-1.27)
Body mass index (kg/m2)
≥30 2793 1.68 (46) 1.66 (44) 1.01 (0.67-1.53) .32
b30 2849 1.81 (49) 2.62 (70) 0.69 (0.48-1.00)
Prior stroke or TIA
Yes 1785 2.80 (47) 3.24 (52) 0.86 (0.58-1.28) .75
No 3862 1.27 (48) 1.67 (62) 0.78 (0.53-1.14)
Hypertension
Yes 5389 1.76 (91) 2.15 (109) 0.82 (0.62-1.09) .78
No 258 1.44 (4) 2.05 (5) 0.72 (0.19-2.68)
Heart failure
Yes 3764 1.62 (57) 2.07 (73) 0.80 (0.56-1.13) .78
No 1882 1.97 (38) 2.29 (41) 0.85 (0.55-1.33)
Prior VKA
Yes 3687 1.54 (56) 1.87 (67) 0.84 (0.59-1.20) .76
No 1960 2.17 (39) 2.72 (47) 0.77 (0.51-1.19)
Concurrent ASA use
Yes 2104 1.67 (33) 1.90 (37) 0.89 (0.56-1.43) .72
No 3543 1.78 (62) 2.28 (77) 0.78 (0.56-1.09)
Baseline renal function
eGFR ≤60 (mL/min) 1860 2.25 (39) 3.14 (56) 0.72 (0.47-1.08) .56
eGFR N60 (mL/min) 3782 1.51 (56) 1.64 (58) 0.91 (0.63-1.31)
Nondiabetic subgroup 8524 2.12 (174) 2.32 (192) 0.92 (0.75-1.13) –
B. Ischemic stroke
Diabetic subgroup
Diabetes controlled by .55
Insulin 930 1.76 (15) 1.40 (13) 1.37 (0.65-2.87)
Oral medication 3283 1.42 (46) 1.48 (46) 0.94 (0.62-1.42)
Diet 1433 0.94 (13) 1.43 (19) 0.66 (0.33-1.35)
Body mass index (kg/m2) .037
≥30 2793 1.35 (37) 0.86 (23) 1.56 (0.93-2.63)
b30 2849 1.36 (37) 2.04 (55) 0.66 (0.43-1.01)
Prior stroke or TIA
Yes 1785 2.44 (41) 2.28 (37) 1.06 (0.68-1.66) .63
No 3862 0.87 (33) 1.10 (41) 0.81 (0.51-1.28)
Hypertension .66
Yes 5389 1.37 (71) 1.43 (73) 0.96 (0.69-1.33)
No 258 1.08 (3) 2.05 (5) 0.53 (0.13-2.24)
Heart failure .25
Yes 3764 1.34 (47) 1.18 (42) 1.16 (0.76-1.75)
No 1882 1.39 (27) 2.01 (36) 0.68 (0.41-1.12)
Prior VKA .89
Yes 3687 1.26 (46) 1.38 (50) 0.93 (0.62-1.39)
No 1960 1.54 (28) 1.60 (28) 0.93 (0.55-1.58)
Concurrent ASA use .63
Yes 2104 1.26 (25) 1.12 (22) 1.14 (0.64-2.02)
No 3543 1.40 (49) 1.65 (56) 0.85 (0.58-1.25)
Baseline renal function (mL/min) .43
eGFR ≤60 1860 1.72 (30) 2.28 (41) 0.75 (0.47-1.21)
eGFR N60 3782 1.18 (44) 1.04 (37) 1.12 (0.72-1.74)
Nondiabetic subgroup 8524 1.60 (132) 1.56 (130) 1.03 (0.81-1.31) –
(continued on next page)
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N
Rivaroxaban
events/100 pt-yrs
(total events)
Warfarin
events/100 pt-yrs
(total events)
Rivaroxaban vs
warfarin HR
(95% CI)
P value for interaction
of subgroup⁎ with
treatment
C. Major or NMCR bleeding
Diabetic subgroup
Diabetes controlled by .27
Insulin 937 16.54 (98) 16.19 (106) 1.03 (0.78-1.37)
Oral medication 3292 14.80 (345) 14.64 (330) 1.05 (0.90-1.22)
Diet 1453 13.83 (139) 16.81 (160) 0.85 (0.68-1.07)
Body mass index (kg/m2) .16
≥30 2810 13.82 (280) 15.64 (303) 0.91 (0.77-1.08)
b30 2868 15.90 (302) 15.20 (292) 1.08 (0.92-1.27)
Prior stroke or TIA .30
Yes 1800 14.93 (182) 14.66 (176) 1.08 (0.87-1.33)
No 3883 14.76 (400) 15.79 (420) 0.96 (0.84-1.10)
Hypertension .053
Yes 5422 14.50 (543) 15.58 (575) 0.97 (0.86-1.09)
No 261 21.35 (39) 12.25 (21) 1.74 (1.00-3.01)
Heart failure .15
Yes 3787 14.05 (356) 15.82 (403) 0.93 (0.81-1.08)
No 1895 16.24 (226) 14.69 (193) 1.13 (0.93-1.37)
Prior VKA .37
Yes 3708 15.67 (413) 15.64 (414) 1.02 (0.88-1.17)
No 1975 13.07 (169) 15.00 (182) 0.94 (0.76-1.16)
Concurrent ASA use .43
Yes 2108 16.62 (225) 17.35 (233) 1.01 (0.84-1.22)
No 3575 13.86 (357) 14.41 (363) 0.98 (0.84-1.14)
Baseline renal function (mL/min) .45
eGFR ≤60 1880 17.69 (205) 18.85 (227) 0.99 (0.82-1.20)
eGFR N60 3798 13.62 (377) 13.91 (369) 0.99 (0.86-1.15)
Nondiabetic subgroup 8553 14.99 (893) 13.94 (853) 1.09 (0.99-1.20) –
D. Intracranial hemorrhage
Diabetic subgroup
Diabetes controlled by
Insulin 937 0.30 (2) 0.54 (4) 0.57 (0.10-3.11) .27
Oral medication 3292 0.46 (12) 1.05 (27) 0.45 (0.23-0.89)
Diet 1453 0.70 (8) 0.45 (5) 1.64 (0.54-5.03)
Body mass index (kg/m2)
≥30 2810 0.35 (8) 0.81 (18) 0.44 (0.19-1.02) .49
b30 2868 0.65 (14) 0.82 (18) 0.83 (0.41-1.68)
Prior stroke or TIA
Yes 1800 0.66 (9) 1.03 (14) 0.64 (0.28-1.48) .95
No 3883 0.42 (13) 0.72 (22) 0.63 (0.32-1.26)
Hypertension
Yes 5422 0.50 (21) 0.83 (35) 0.64 (0.37-1.10) .95
No 261 0.45 (1) 0.51 (1) 0.72 (0.05-11.6)
Heart failure
Yes 3787 0.35 (10) 0.83 (24) 0.47 (0.22-0.99) .47
No 1895 0.74 (12) 0.80 (12) 0.92 (0.41-2.04)
Prior VKA
Yes 3708 0.43 (13) 0.69 (21) 0.64 (0.32-1.28) .95
No 1975 0.63 (9) 1.09 (15) 0.63 (0.27-1.45)
Concurrent ASA use
Yes 2108 0.52 (8) 0.77 (12) 0.69 (0.28-1.69) .92
No 3575 0.48 (14) 0.84 (24) 0.60 (0.31-1.17)
Baseline renal function (mL/min)
eGFR ≤60 1880 0.75 (10) 1.01 (14) 0.75 (0.33-1.68) .83
eGFR N60 3798 0.39 (12) 0.73 (22) 0.56 (0.28-1.14)
Nondiabetic subgroup 8553 0.49 (33) 0.69 (48) 0.72 (0.46-1.12) –
Abbreviations: pt-yrs, Patient-years; HR, hazard ratio; TIA, transient ischemic attack; VKA, vitamin K antagonist; ASA, aspirin; eGFR, estimated glomerular filtration rate.
⁎ Includes nondiabetic patients as one of the subgroups.
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Supplementary Table V. Confirmatory analyses in propensity score–matched groups
Confirmatory analysis. A sensitivity analysis was conducted in which a subset of nondiabetic group was chosen to most closely match the diabetic group, using
propensity score matching.
Matching process:
As diabetic patients were the smaller group, patients were selected from the nondiabetic group to match those in the diabetic group, in a 1:1 ratio, using the
following process:
1. Candidate covariates. Variables in online Appendix Supplementary Table I, except for diabetes-specific variables and CHADS2 score, comprised the
starting list. Any variable missing in 15% or more of patients in either group was dismissed from further consideration. For any variable missing in b15%
of patients in both groups, missing values were imputed using the group-specific median for continuous variables and mode for categorical variables.
2. Trimming. For continuous variables remaining after the first step, nondiabetic patients whose value was below the minimum or above the maximum for
diabetic patients were excluded.
3. Propensity model. A propensity model was developed using multiple logistic regression in which the dependent (outcome) variable was an indicator of
whether each patient is diabetic, and the independent (predictor) variables were the baseline variables remaining after step 1. Continuous predictors
were evaluated for the linearity of their relationship with the outcome, and restricted cubic splines used as needed to accommodate nonlinearity. From
this model, an estimated probability of being a diabetic patient and a corresponding logit (loge[p/(1 − p)]) were calculated for each patient.
4. Matching (Rosenbaum and Rubin method⁎). A caliper width of 0.15*(standard deviation of the logit) was used. For a given diabetic patient, all
nondiabetic patients were considered whose logit differed from the diabetic patient's logit by less than the caliper width; among these patients, the
nondiabetic patient with the shortest Mahalanobis distance from the diabetic patient was selected as the match. (Variables used in calculating
Mahalanobis distance were all significant predictors from the propensity model.) If there were no nondiabetic patients within the caliper width, the
diabetic patient was omitted from the analysis. Each nondiabetic patient could be selected only once. The multiplier for the caliper width (0.15) was
chosen to allow the largest sample size while ensuring a standardized difference of b10% on the key variables of age, body mass index, estimated
glomerular filtration rate, and prior stroke or TIA, and, as far as possible, all P N .05 for these 4 variables. Standardized difference is defined as the
difference in means (or proportions) divided by the average standard deviation.
This matching process resulted in a cohort of 3999 diabetic patients (70% of the original cohort) and the same number of matched nondiabetic patients. The
matched cohorts were then compared as in the main analyses. Baseline characteristics before and after matching are shown in online Appendix
Supplementary Table VIA and B, and model results are shown in online Appendix Supplementary Table VIC and D.
⁎Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39(1):33–38.
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Supplementary Table VI. Propensity score–matched cohorts
A. All
Baseline characteristic
All nondiabetic
patients (n = 8569)
All diabetic
patients (n = 5695)
% Standardized
difference P
Age (y) 74 (66, 79) 71 (64, 77) 16 b.0001
Female 40% (3418) 39% (2242) 1 .53
Persistent AF 80% (6864) 82% (4684) 5 .0013
Baseline BMI (kg/m2) 27 (24, 30) 30 (27, 34) 53 b.0001
Baseline—systolic pressure 130 (120, 140) 130 (120, 140) 7 b.0001
Baseline—diastolic pressure 80 (71, 86) 80 (70, 85) 9 b.0001
GFR (Cockcroft and Gault) 65 (50, 83) 72 (55, 94) 31 b.0001
History—stroke or TIA 66% (5662) 32% (1806) 73 b.0001
History—hypertension 87% (7477) 95% (5433) 29 b.0001
History—CHF 60% (5116) 67% (3792) 14 b.0001
History—COPD 10% (835) 12% (662) 6 .0004
VKA use at screening 61% (5187) 65% (3717) 10 b.0001
Chronic ASA at screening 36% (3093) 37% (2112) 2 .23
ACE inhibitor/ARB at baseline 70% (5957) 81% (4626) 27 b.0001
β-Blocker at baseline 63% (5416) 67% (3834) 9 b.0001
Calcium-channel blocker at baseline 25% (2151) 32% (1807) 15 b.0001
Diuretic at baseline 54% (4670) 67% (3820) 26 b.0001
CHADS2 score 5 or 6⁎ 9% (801) 23% (1294) 37 b.0001
B. Matched
Baseline characteristic
Matched nondiabetic
patients (n = 3999)
Matched diabetic
patients (n = 3999)
% Standardized
difference P
Age (y) 75 (67, 78) 73 (66, 78) 7 .0011
Female 41% (1622) 41% (1631) 0 .84
Persistent AF 83% (3329) 82% (3262) 4 .049
Baseline BMI (kg/m2) 29 (26, 32) 28 (26, 32) 0 .97
Baseline—systolic pressure 130 (120, 140) 130 (120, 140) 0 .94
Baseline—diastolic pressure 80 (70, 85) 80 (70, 85) 2 .41
GFR (Cockroft and Gault) 66 (52, 84) 67 (52, 86) 4 .099
History—stroke or TIA 46% (1844) 44% (1778) 3 .14
History—hypertension 94% (3771) 94% (3752) 2 .37
History—CHF 64% (2565) 64% (2567) 0 .95
History—COPD 11% (454) 11% (432) 2 .43
VKA use at screening 64% (2572) 64% (2543) 2 .50
Chronic ASA at screening 36% (1450) 37% (1488) 2 .38
ACE inhibitor/ARB at baseline 78% (3121) 77% (3097) 1 .52
β-Blocker at baseline 65% (2598) 66% (2624) 1 .54
Calcium-channel blocker at baseline 30% (1180) 29% (1154) 1 .52
Diuretic at baseline 64% (2545) 62% (2486) 3 .17
CHADS2 score = 5 or 6⁎ 7% (275) 31% (1254) 66 b.0001
Outcomes
Diabetic patients vs
nondiabetic patients,
HR (95% CI)
P value for diabetic
vs nondiabetic
patients
Diabetic
patients—rivaroxaban
vs warfarin HR
(95% CI)
Nondiabetic
patients—rivaroxaban
vs warfarin HR
(95% CI)
P value for
interaction of
diabetes and
treatment
C. Diabetic vs matched nondiabetic patients
Primary efficacy: stroke or systemic embolism 1.23 (0.99-1.53) .066 0.81 (0.60-1.10) 0.95 (0.69-1.30) .49
Primary safety: major or NMCR bleeding 0.99 (0.90-1.09) .82 1.00 (0.87-1.15) 1.16 (1.01-1.32) .13
D. Original results using the unmatched patients
Primary efficacy: stroke or systemic embolism 1.13 (0.94-1.35) .20 0.82 (0.63-1.08) 0.92 (0.75-1.13) .53
Primary safety: major or NMCR bleeding 1.02 (0.94-1.10) .62 0.98 (0.88-1.10) 1.09 (0.99-1.20) .17
% Standardized difference = 100*(mean(Diab) − mean(NonDiab))/sqrt((var(Diab) + var(NonDiab))/2).
Overall, the 2 sets of results were nearly identical.
Abbreviations: HR, hazard ratio; NMCR, nonmajor clinically relevant.
⁎ Included for illustration but not used in matching.
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Supplementary Figure 1
Efficacy end points.
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Supplementary Figure 2
Safety end points.
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